Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Accounts Payables: 2022-2025

Historic Accounts Payables for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $5.4 million.

  • Taysha Gene Therapies' Accounts Payables rose 10.26% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 10.26%. This contributed to the annual value of $3.6 million for FY2024, which is 43.58% down from last year.
  • As of Q3 2025, Taysha Gene Therapies' Accounts Payables stood at $5.4 million, which was down 29.50% from $7.7 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Accounts Payables ranged from a high of $24.0 million in Q2 2022 and a low of $3.6 million during Q4 2024.
  • Over the past 3 years, Taysha Gene Therapies' median Accounts Payables value was $7.5 million (recorded in 2023), while the average stood at $7.2 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first plummeted by 59.08% in 2023, then climbed by 15.31% in 2024.
  • Taysha Gene Therapies' Accounts Payables (Quarterly) stood at $10.9 million in 2022, then slumped by 41.84% to $6.4 million in 2023, then slumped by 43.58% to $3.6 million in 2024, then increased by 10.26% to $5.4 million in 2025.
  • Its Accounts Payables stands at $5.4 million for Q3 2025, versus $7.7 million for Q2 2025 and $4.3 million for Q1 2025.